Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given a consensus recommendation of "Buy" by the nine research firms that are presently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $22.29.

ZVRA has been the subject of a number of analyst reports. Canaccord Genuity Group increased their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. JMP Securities set a $18.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Finally, Wall Street Zen upgraded shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA traded up $0.19 during mid-day trading on Monday, hitting $8.52. 229,490 shares of the company's stock traded hands, compared to its average volume of 644,130. The company's 50-day moving average is $7.62 and its two-hundred day moving average is $8.08. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The company has a market capitalization of $465.82 million, a P/E ratio of -4.32 and a beta of 1.87. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The business had revenue of $20.40 million for the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the prior year, the firm earned ($0.40) EPS. On average, equities analysts anticipate that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director John B. Bode purchased 10,000 shares of the company's stock in a transaction on Wednesday, March 19th. The stock was acquired at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the transaction, the director now directly owns 40,000 shares in the company, valued at approximately $318,400. The trade was a 33.33% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 2.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Zevra Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Zevra Therapeutics by 6.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock valued at $238,000 after acquiring an additional 1,812 shares during the last quarter. IFG Advisors LLC grew its holdings in shares of Zevra Therapeutics by 10.0% in the fourth quarter. IFG Advisors LLC now owns 29,050 shares of the company's stock valued at $242,000 after purchasing an additional 2,650 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Zevra Therapeutics by 19.6% in the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after purchasing an additional 3,007 shares in the last quarter. Corebridge Financial Inc. grew its holdings in shares of Zevra Therapeutics by 16.9% in the fourth quarter. Corebridge Financial Inc. now owns 26,294 shares of the company's stock valued at $219,000 after purchasing an additional 3,801 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Zevra Therapeutics by 2.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company's stock valued at $1,148,000 after purchasing an additional 3,827 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.